LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of a new clinical research abstract at the 40th annual Fall Clinical Dermatology Conference (“Fall Clinical 2020”). Held virtually this year, Fall Clinical 2020 offers comprehensive workshops and sessions highlighting the latest advances in the diagnoses and treatment of various conditions related to medical, surgical and cosmetic dermatology, including new tools and resources in patient management.
The clinical research abstract “Combining DNA and RNA analyses enhances non-invasive early detection of cutaneous melanoma,” presented by Stephanie R Jackson Cullison, MD, PhD, of the Department of Dermatology, New York University School of Medicine, highlighted the improvement of the DermTech Pigmented Lesion Assay by combining RNA and DNA analyses to create a new test, termed PLAplus. The research from both Dr. Jackson and Dr. Laura K Ferris, MD, PhD, of the Department of Dermatology, University of Pittsburgh further validated that increasing genomic atypia, which may precede morphologic atypia, can be found on the spectrum of pigmented skin lesions from benign nevi to melanoma. DermTech’s clinical research abstract also published in SKIN, The Journal of Cutaneous Medicine.
“PLAplus combines gene expression analyses with TERT promoter mutation analyses, elevating the test’s overall sensitivity from 91% to 97% as compared to the PLA test. This increased sensitivity allows dermatologists to catch significantly more early stage melanomas and gives a genomic rather than exclusively morphologic rationale to guide biopsy decisions,” said Dr. Ferris.
DermTech was also included in the following sessions presented at Fall Clinical 2020: “Integrating Technology into Your Practice,” “Devices in Skin Cancer” and “Gene Expression Profiling.”
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including the PLAplus, and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10 Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.